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IMPROVED METHODS OF MEASURING THE LATENT HIV RESERVOIR 
WITH DNA SIZE SELECTION AND DROPLET DIGITAL PCR 
YUNDA WANG 
ABSTRACT 
 For HIV-infected patients undergoing antiretroviral treatment (ART), the 
latent reservoir is a major barrier to cure. Formed in the acute stages of infection, 
the latent reservoir consists of cells in the host’s body where HIV can hide from 
the immune system and remain in a quiescent state. When a patient stops ART, 
the virus quickly rebounds, proliferates, and begins infecting more cells. The 
majority of assays available to measure the latent HIV reservoir measure HIV 
DNA and RNA using polymerase chain reaction (PCR). However, these methods 
can overestimate the reservoir size, because unintegrated and replication-
incompetent DNA comprise a larger proportion of HIV nucleic acids than does 
replication competent HIV provirus. 
To measure integrated HIV DNA from infected donor samples provided 
by the HIV Reservoir Assay Validation and Evaluation Network (RAVEN) and 
The University of Texas Health Sciences Center at Houston (UTHealth), I applied 
pulsed-field gel electrophoresis (PFGE) to reduce the amount of unintegrated 
HIV DNA such as episomal 2-long-terminal-repeat (2-LTR) circles before 
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quantitation with droplet digital PCR (ddPCR). This assay could prove useful to 
measure changes in the latent HIV reservoir, especially in clinical trials that aim 
to reduce its size through a variety of compounds.  
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 Before the introduction of ART in the late 1980s, infected 
individuals with HIV rarely survived for more than ten years. ART refers to any 
HIV treatment regimen that uses a combination of two or more drugs to combat 
the infection. Patients on ART with different combinations of protease, reverse 
transcriptase, and integrase inhibitors can have a close to normal life span and 
quality of life. However, ART can cause adverse long-term side effects, which 
can be problematic in decreasing patient adherence to the drug regimens. Figure 
1 illustrates key steps in the HIV replication cycle cascade targeted by inhibitors 
to halt the production of viral particles. These steps include envelope fusion, 
RNA reverse transcription, and integration into the host genome (Arts & 
Hazuda, 2012).  
HIV morbidity has been decreased dramatically due to ART, but a 
significant number of people with limited or no access to treatment still die each 
year. In addition, there was an estimated 1.7 million new infections in 2019 alone, 
according to UNAIDS. Without medication, HIV rapidly destroys the immune 
system and progressively evolves to Acquired Immunodeficiency Syndrome 
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(AIDS). Those who have arrived at this end of stage of HIV infection become 
extremely prone to opportunistic infections (OIs) by bacteria, viruses, fungi, and 
parasites. Pneumococcal pneumonia, tuberculosis (TB), and Mycobacterium 
avium complex (MAC) infections are just a few examples of deadly illnesses that 
can arise as a result of the body’s weakened immune system (Benito et al., 2012). 
The body’s compromised immune surveillance also makes it more difficult to 






Figure 1. Schematic Description of the Mechanism of the Four Classes of 
Currently Available Antiretroviral Drugs against HIV. 
Fusion inhibitors (interfere with the binding, fusion or entry of an HIV virion), 
reverse-transcriptase inhibitors (interfere with the transcription of viral RNA into 
DNA), integrase inhibitors (block the viral enzyme integrase, that inserts the 
viral genome into the DNA of the host cell), protease inhibitors (block proteolytic 
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cleavage of protein precursors that are necessary for the production of infectious 
viral particles). Taken from (Splettstoesser, 2013). 
 
HIV Latency 
ART prevents ongoing HIV replication, but once it is disrupted, HIV 
rapidly rebounds and begins to infect other cells again. This suggests the 
existence of a latent reservoir – a sanctuary site in previously infected cells for 
dormant viruses to hide in. By definition, a latent viral reservoir can preserve 
some quantity of replication competent virus to provide the capacity to continue 
future progenies (Saksena et al., 2010). Furthermore, the latent HIV reservoir is 
established quite early during the acute phase of infection and persists even 
when the viral load is undetectable in blood (Vanhamel et al., 2019).  
Many clinical studies have been conducted to assess the natural decay of 
the latent HIV reservoir. In one cohort of 30 to 101 individuals, the reservoir half-
life was estimated to be around 44 months. In another cohort of 101 individuals 
on ART and virally suppressed for a minimum of 4 years, the half-life was 
estimated to be closer to 13 years. This suggests that without a cure, the “natural” 
eradication of HIV from the body seems highly unlikely in one’s lifetime 
(Bachmann et al., 2019). 
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The latent HIV reservoir exists both cellularly and anatomically. Figure 2 
illustrates several key sites of the latent HIV reservoir, but it is still unclear 
whether all of these sites contribute to viral rebound once ART has stopped. 
Cellularly, it is widely agreed upon that the resting memory CD4+ T lymphocyte 
population is the major site for HIV persistence. On average, it is estimated that 
one in one million CD4+ T lymphocytes is latently infected with replication-
competent virus (Hodel et al., 2016). As the primary target of HIV infection, this 
is also the reason why there is rapid destruction and depletion of CD4+ T 
lymphocytes in afflicted individuals (Saksena et al., 2010). HIV enters the cell 
primarily through CCRR5 or CXCR4 co-receptors and then CD4 receptors on the 
CD4+ T lymphocyte surface. Binding to these leads to subsequent fusion of the 
viral and host cell membranes and entry of viral proteins and nucleic acids. 
Anatomically, HIV spreads through the bloodstream to different areas of 
the body within a couple of days. Infected cells have been discovered in the 
lungs, kidneys, gastrointestinal (GI) tract, reproductive tract, as well as the 
central nervous system (CNS). While some anatomical sites are relatively easy to 
reach with current drug regimens, the CNS is relatively protected by the blood-





Figure 2. Reservoirs of HIV-1 Persistence in HAART. 




Once the latent HIV reservoir has been established, it can be maintained 
by several mechanisms illustrated in Figure 3. For example, transcriptional 
factors required in the nucleus such as Nuclear Factor- κB (NF- κB) or Nuclear 
Factor of Activated T Cells (NFAT) can be sequestered in the cytoplasm, leading 
to transcriptional silencing. Furthermore, epigenetic regulation by Histone 
Deacetylases (HDACs) and Histone Methyltransferases (HMTs) can reinforce a 
strong transcriptional block. Finally, transcription elongation factors such as the 
Transcriptional Elongation Factor B (p-TEFB) Complex can also be sequestered 





Figure 3. Mechanisms Involved in the Maintenance of HIV-1 Latency and 
Strategies to Disrupt Latency. 









 Currently, there are approaches to HIV cures in development: a sterilizing 
cure and a functional cure. The former aims to completely remove HIV from the 
body whereas the latter aims to enable the body to control viral replication on its 
own. However, the existence of a latent reservoir has become a major barrier to 
cure efforts and many strategies have shifted focus in an attempt to reduce its 
size. 
 One method proposed to destroy the latent HIV reservoir is the “Shock 
and Kill” or “Kick and Kill” strategy. This approach combines latency reversal 
agents (LRAs) to activate latently infected cells while continuing ART to prevent 
new infections. The reawakened cells would once again begin viral transcription 
and translation, and allow cytotoxic CD8+ T lymphocytes (CTLs) or natural killer 
(NK) cells to identify them and flush them out of the body. Notable LRAs 
include protein kinase C (PKC) agonists and histone deacetylase (HDAC) 
inhibitors, which upregulate HIV transcription through signal cascades or 
epigenetic modification of chromatin, respectively (Castro-Gonzalez et al., 2018). 
in preliminary trials with HIV-infected humanized mouse models on ART 
suppression, it was shown that the 3B3-PE38, an immunotoxin that targets HIV 
envelope glycoproteins, can be used to deplete latently infected cells in vivo 
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(Denton et al., 2014). Of course, limitations to this approach cannot be neglected. 
LRAs can be inefficient at disrupting latency in certain areas of the body and side 
effects of these compounds have not been studied extensively. 
Recently, CRISPR/Cas9 has been proposed for an HIV cure as gene 
therapy garners more and more attention in the biomedical field. The 
CRISPR/Cas9 complex – originally observed in bacteria as a defense against 
viruses – could bind to single-guide RNAs (sgRNAs) transcribed from 
palindrome sequences of the host genome and make endonucleolytic cuts in 
complementary DNA sequences. DNA repair mechanisms are activated, and the 
double-stranded DNA breaks can be modified by deletion or insertion, then 
integration. Researchers have successfully excised integrated HIV provirus in 
animal models using an adeno-associated virus (AAV) vector to deliver single-
guide RNAs and the Cas9 endonuclease derived from Staphylococcus aureus 
(Yin et al., 2017). Results demonstrated significant deletions of HIV proviral 
DNA in a number of tissues – including the brain, lungs, kidneys, and spleen. 
Since then, there has been additional research conducted to repurpose the 
Cas9 endonuclease for an “Lock and Block” strategy. Illustrated in Figure 4, a 
catalytically inactive Cas9 endonuclease is paired with repressors targeted at 
specific HIV promotors to modulate its transcriptional activity. Specifically, 
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Kruppel-associated box (KRAB) zinc-finger proteins have been reported to 
repress HIV transcription through further signaling cascades featuring KRAB-
associated protein 1 (KAP1) and other corepressors (Olson et al., 2019). With the 
ethical issues surrounding gene editing, this repurposed approach to Cas9 may 
offer a more reasonable and acceptable method of epigenetically repressing the 
production of new virions. 
 
 
Figure 4. A Modular RNA-Guided Genome Regulation Platform. 
dCas9 fused to effector domains can serve as an RNA guided DNA binding 





 Similarly, other compounds such as Didehydro-Cortistatin (dCA) have 
also been explored in HIV-infected humanized mouse models for the delay and 
reduction of viral rebound after ART interruption. Compared to viral 
suppression under ART, dCA was shown to promote further epigenetic silencing 
by inhibiting the Tat protein from recruiting necessary transcriptional factors to 
the HIV promoter (Kessing et al., 2017). 
 
Measuring Changes in the Latent HIV Reservoir 
 In order to validate the effectiveness of existing and future cure strategies, 
it is necessary to have assays that can measure changes to the HIV latent 
reservoir with accuracy, precision, and reproducibility. 
The gold standard for quantifying the size of the latent reservoir is the 
quantitative viral outgrowth assay (QVOA). Illustrated in Figure 5, the QVOA is 
a terminal dilution culture assay in which resting CD4+ T lymphocytes are 
reactivated with an LRA. The virus is then expanded using uninfected cells and 
the amount of viral protein p24 is assessed with an enzyme-linked 
immunosorbent assay (ELISA) (Massanella & Richman, 2016). Ultimately, the 
results can be reported as an Infectious Units per Million (IUPM) value with a 
95% confidence interval (Rosenbloom et al., 2015). Compounds used to reverse 
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latency have included phytohemagglutinin (PHA), antibodies for CD3/CD28, 
and Phorbol Myristate Acetate (PMA) paired with Ionomycin. Uninfected cells 
for viral amplification can range from HIV-negative CD4+ T lymphocytes and 
human T lymphoblast cell lines such as MOLT-4. 
However, besides being time-consuming, labor-intensive, and expensive, 
the QVOA significantly underestimates the size of the latent HIV reservoir. This 
underestimation largely stems from the incomplete activation of latently infected 
cells in culture; it has been reported that nearly 12% of proviruses that are 
replication competent, are not successfully activated by LRAs like PHA (Ho et 
al., 2013).  
The latent HIV reservoir may also differ between different cellular or 
anatomical sites. The frequency of HIV genomes was shown to be higher in 
transitional and central memory cells than effector memory cells (Murray et al., 
2016). Both the ileum and rectum had higher HIV DNA levels in CD4+ T 
lymphocytes than blood (Yukl et al., 2013). Patient-to-patient variability also 




Figure 5. The Standard and Modified QVOA. 
Taken from (Laird et al., 2013). 
 
PCR assays are faster, cheaper, and require less cells than QVOA because 
they analyze more frequent events. However, the detection of total HIV DNA by 
PCR overestimates the size of the latent reservoir, because PCR assays also detect 
forms of unintegrated DNA such as 1-LTR, 2-LTR circles, and also replication 
incompetent proviruses.  
To account for these unintegrated DNA fragments, the Alu-gag qPCR was 
introduced. This has been the most common method of measuring truly 
integrated HIV DNA in the latent reservoir. In the first step, one primer is 
anchored to Alu repeat elements in the human genome while the other is 
anchored to gag, an HIV gene that encodes to the structural components of the 
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virion. In the second step, primers within the HIV long terminal repeat (LTR) 
region will detect HIV specific products that can be quantitated by comparing 
the resultant signals to those from a standard (Liszewski et al., 2009). Thus, while 
unintegrated HIV DNA is still linearly amplified, integrated HIV DNA is 
preferentially and exponentially amplified, leading to much stronger signals. 
In contrast to the traditional qPCR, ddPCR utilizes a water-oil emulsion 
droplet system which allows for DNA templates to be individually partitioned. 
PCR amplification is then carried out within each droplet, leading to increased 
precision, higher signal-to-noise ratios, and the removal of PCR bias.  
RNA assays, such as the Inducible Cell-Associated RNA Expression in 
Dilution (iCARED) assay, are also promising methods of measuring the latent 
HIV reservoir. This method more sensitive, faster, and has a higher throughput 
than the standard QVOA. Similar to the QVOA, CD4+ T lymphocytes are 
isolated and plated in three-fold dilutions in the presence of Raltegravir to 
prevent viral propagation. After a three-day culture, both cell-associated and 
cell-free RNA are extracted with an automated platform and magnetic beads. 
Then, ddPCR is used to target specific sequences such as gag or tat/rev and an 
IUPM value is calculated. The regions of tat/rev are only present in HIV 
fragments that have completed post-transcriptional splicing and indicate more 
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likely replication competence. Compared to the QVOA, the iCARED assay 
reports a latent HIV reservoir size 13 times larger. Compared to the total HIV 
DNA assay, the iCARED assay reports a latent HIV reservoir size 19 times 
smaller. (Massanella et al., 2015). 
Table 1 illustrates a summary of the aforementioned assays to measure the 
latent HIV reservoir. When time is a factor, PCR assays are generally more 
preferable than culture assays. When higher sensitivity is required, ddPCR 
should be the detection method of choice. Each method has its pros and cons, but 
it is crucial to the development of an HIV cure that these assays have the ability 









Table 1. Characteristics of Assays for Measuring the Latent HIV Reservoir. 






 Although the Alu-gag qPCR assay is widely used for measuring 
integrated viral DNA, there are certain limitations to this method. First, this 
assay requires a large quantity of DNA material for downstream amplification. 
Second, there is uncertainty as to the distance between the Alu sequence and the 
site of HIV integration and many believe that this could lead to the 
underestimation of integrated gag copies. Finally, qPCR has a lower sensitivity 
for the detection of rare events and relies on a standard curve for an indirect 
measurement of the latent HIV reservoir. 
To address these challenges, I planned to validate and optimize an 
automated PFGE platform that could eliminate unintegrated HIV fragments such 
as 2-LTR circles. I also wanted to use ddPCR to analyze HIV DNA from clinical 
samples to show that its absolutely measurement of the latent reservoir was 
accurate, precise, repeatable, and easy. Lastly, I was interested to see if the 
increased sensitivity of ddPCR could detect very low copy numbers in the latent 
HIV reservoir of a baby born to an infected mother. This case is particularly 
interesting because the baby was treated for a year but has tested negative since 
then. By performing these tests on well-studied and ongoing projects, my 
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ultimate goal was to better understand and further assess the pros and cons of 




MATERIALS & METHODS 
 
Study Subjects 
 Samples of frozen PBMCs from chronically infected donors in the RAVEN 
project, who had been suppressed on ART for over a year, were stored in freeze 
medium containing 90% FBS and 10% Dimethyl Sulfoxide DMSO. Prior to DNA 
extraction, samples were rapidly thawed in a water bath at 37 °C. 
 Samples of frozen PBMCs from a four-year-old infant born to a 
chronically-infected HIV-positive mother was also stored and thawed as above. 
Additionally, CD4+ T lymphocytes were purified from the PBMCs using the 
EasySep Human CD4+ T Cell Isolation Kit from STEMCELL Technologies Inc. 
Cell count and phenotyping were performed with the Accuri C6 Plus from BD 
Biosciences. 
 HIV-1 Infected U937 (U1) cells obtained from the NIH AIDS Reagent 
Program have been used as a model to study HIV latency. The U1 cells contain 
an integrated proviral HIV genome that is defective in tat function as well as 
unintegrated 2-LTR circles. Following the NIH AIDS Reagent Program 
Guidelines, the U1 cells were propagated using 90% RPMI-1640 containing 2.0 
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mM L-Glutamine, 10% FBS, with Penicillin and Streptomycin added to a final 
concentration of 100 U/mL and 100 µg/mL respectively. 
 
DNA Extraction 
  Cellular DNA was extracted using the QIAamp DNA Blood Midi Kit from 
QIAGEN. PBMCs or CD4+ T lymphocytes were washed and resuspended with 
PBS at 200 μL prior to the addition of the lysis buffer. Per the manufacturer’s 
recommendation, two elution steps with Buffer AE were performed to maximize 
yield and the Buffer AE was allowed to incubate in the spin column for five 
minutes prior to centrifugation.  
 
Ethanol Precipitation 
 1/10 volume of 3M Sodium Acetate, 2 μL of Glycogen, and 2 volumes of 
100% Ethanol were added in order to the extracted DNA. Once the solution was 
gently mixed by inversion and stored at negative 20 °C overnight, the precipitate 
was centrifuged at >10,000 x g for 30 minutes at 4 °C and the supernatant was 
discarded. Following a wash with 1mL of freshly-made 70% Ethanol at >10,000 x 
g for 10 minutes at 4 °C, the supernatant was carefully removed without 
disrupting the DNA pellet and allowed to airdry. Finally, the dried DNA pellet 
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was resuspended with 35 μL of pre-heated Buffer AE at 60 °C from the QIAamp 
DNA Blood Midi Kit from QIAGEN. 
 
Measuring DNA Concentration 
 1.5 μL of DNA was used on the NanoDrop One/OneC Microvolume UV-
Vis Spectrophotometer from Thermo Scientific to estimate the DNA 
concentration (ng/ μL), the A260/A280 absorptivity ratio, and the A260/A230 
absorptivity ratio.  
 
BluePippen PFGE 
 The BluePippen platform from Sage Science was used to purify the high 
molecular weight DNA species. Before each run, the platform was cleaned with 
the manufacturer’s wash cassette filled with DI water and optically calibrated 
with the provided fixture. 
 Two types of gel cassettes were tested to optimize the assay: the 0.75% 
Agarose, 4 – 20 kb High Pass Cassette and the High Pass Plus Cassette for >15 kb 
DNA Size Collections. The former allows a maximum DNA load of 5 ug diluted 
to a final volume of 30 μL (166 ng/ μL) and the latter allows a maximum DNA 
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load of 10 ug diluted to a final volume of 30 μL (332 ng/μL). The final run 
volume of 40 μL was obtained after the addition of 10 μL of loading solution.  
 For both gel cassettes, four lanes were utilized for the DNA samples and 
one lane was reserved for a molecular weight marker. 15 kb was set as the 
molecular weight cutoff mark and the total run time ranged from 4 to 6 hours 
depending on the gel cassette. Images of the two types of gel cassettes used and 
the program settings are shown in Figure 6 and Figure 7 below. 
 
 




Figure 7. BluePippen High Pass Plus Gel Cassette Program Settings  
 
 Once the entire run was complete, the 0.75% Agarose High Pass Cassette 
yields a total of 40 μL of DNA eluate. 40 μL of 0.1% Tween 20 Buffer were used 
to rinse the remaining DNA in the elution well and added to the initial 40 μL for 
an end volume of 80 μL . The High Pass Plus Cassette, however, yields a total 
DNA eluate volume of 80 μL initially. Similarly, 80 μL of 0.1% Tween 20 Buffer 






Concentrating Post-PFGE DNA 
 The purified DNA was then concentrated using the DNA 120 SpeedVac 
Concentrator from Thermo Scientific. The drying rate was set to 43  °C and the 
runs were repeated at 10-minute increments to make sure the DNA was not 
overly dried. In general, the desired volume was around 35 to 40 μL.  
 
TapeStation Quality Control 
 To analyze the quality of our post-PFGE DNA samples, the concentration 
was normalized and loaded into the 2200 TapeStation system from Agilent. 
Using a Genomic DNA Screentape and DNA Reagents from the manufacturer, 
comparisons between the pre- and post-PFGE DNA samples were made and the 
analysis was visualized through the 2200 TapeStation Software. 
 
Restriction Digest 
 The purified and concentrated DNA samples were restriction digested 
using the BanII enzyme in CutSmart Buffer from New England BioLabs. The 
thermocycler was programmed to incubate at 60 °C for 90 minutes before 





 The following primer-probes were ordered from the Genomics and 
Sequencing Core at the Center of AIDS Research (CFAR) San Diego and used at 
an annealing temperature of 60 °C for the experiments.  
 
 
Table 2. Primer-Probe Information. 
 
 Digested high-molecular-weight DNA samples were emulsified into 
droplets by the QX200 ddPCR System from Bio-Rad following the 
manufacturer’s protocol. 1000 ng of each sample was loaded in triplicate into a 
96-well plate and sealed with a heated PX1 PCR Plate Sealer from Bio-Rad.  Note 
that Low Retention Pippette Tips were also used from Mettler Toledo during 




Table 3. ddPCR Plate Map. 
 
Each 96-well plate can hold a maximum of 24 samples; ¾ of the plate is 
used for the gag & 2-LTR or gag & pol duplex assay and ¼ of the plate is used for 
the RPP-30 singleplex assay. Taking into consideration the dynamic range of the 
QX200 ddPCR system, the digested DNA used for the RPP30 measurements was 
diluted 1:10 before amplification. 
Immediately after the thermocycling steps (95 °C for 10 minutes, 40 
rounds of 94 °C for 30 seconds followed by 58 °C for 60 seconds, and a final 98 °C 
for 10 minutes before returning to a 4 °C infinite hold), the ddPCR plate with 
emulsified samples was read with the QuantaSoft Software from Bio-Rad to 






Data & Statistical Analysis 
 Raw fluorescence data were exported into the QuantaSoft Software from 
Bio-Rad for subsequent analysis. Thresholds were automatically or manually 
generated to distinguish positive, negative, or ambiguous signals on a 1- or 2-D 
graph following a custom algorithm. False positives visualized from a negative 
control and extreme outliers were excluded from the final data set. ddPCR 
template copies per sample were calculated by averaging all replicate wells of a 
particular sample. The number of RPP30 template copies per sample was used to 
compute the total number of cells per sample. 
 Statistical analysis was done using the GraphPad Prism 8.0 Software. HIV 
DNA detection by ddPCR before and after PFGE was compared with Wilcoxon's 







 DNA with a size of >15 kb from U1 cells was purified with PFGE and 
characterized before and after with the 2200 TapeStation. Figure 8 illustrates the 
functional removal of 2-LTR circles from the HIV provirus in U1 cells. Across 
multiple replicates of both the 0.75% Agarose Gel Cassette and the High Pass 
Plus Cassette, a significant amount of DNA <15 kb was filtered out into the 
electrophoresis buffer flow-through. 
 
Size Exclusion Gel Cassettes 
 Using all five lanes, the 0.75% Agarose High Pass Cassette ran for about 
six hours on average. In contrast, the High Pass Plus Cassette only required 
about four hours. 
Both gel cassettes resulted in a substantial decrease of <15 kb DNA species 
following the manufacturer’s default protocols; however, NanoDrop One/OneC 
measurements in Table 4 illustrate that the resultant yield for the former gel 
cassette has an average recovery of around 40% whereas the latter gel cassette 




Figure 8. PFGE Electrophoregram. 
Comparison of DNA from U1 cells before and after running PFGE with the 0.75% 
Agarose High Pass Cassette. Peaks for the U1 Stock and U1 BluePippen were 
measured at 51.468 kb and >60 kb, respectively. The electrophoregram was 
generated by the 2200 TapeStation Software and DNA concentrations were not 




Table 4. DNA Recovery Post-PFGE. 
 
HIV DNA Detection by ddPCR Between Gel Cassettes 
 DNA was extracted from 4 PBMC samples from infected donors 
undergoing ART with suppressed viral loads. HIV gag copies were measured 
and calculated before and after PFGE using the 0.75% Agarose High Pass 
Cassette and the High Pass Plus Cassette. Comparing the data for the gel 
cassettes, Figure 9 illustrates that the 0.75% Agarose High Pass Cassette detects 
more HIV gag copies per 1 million cells. However, the difference is not 
significant (P = 0.25). 
 
HIV DNA Detection by ddPCR Before and After PFGE 
 Despite the removal of lower molecular weight HIV DNA which contain 
gag copies and the further shearing of higher molecular weight HIV DNA by the 
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BluePippen PFGE platform, Figure 9 still illustrates that the calculated gag copies 
per 1 million cells for all samples increased after purification by PFGE. Still, the 
increase from both gel cassettes was not significant (P = 0.125 for both the 0.75% 
Agarose High Pass Cassette and the High Pass Plus Cassette). 
 
 
Figure 9. Comparison of HIV gag Copies per 1 Million Cells by ddPCR 






 We wanted to assess the sensitivity of our assay with these samples since 
the detection of extremely low copy numbers of HIV DNA is challenging. 
PBMCs from a child born to an infected mother were tested for the latent HIV 
reservoir using PFGE and ddPCR. In clinic, the child’s viral load was 
undetectable and its CD4+ T lymphocyte count was normal. We were interested 
to study this subject because the Mississippi Baby had been thought to be 
successfully cured before HIV DNA was detected again in her blood. ddPCR 
data from a previous technician on PBMCs prior to 07/23/2019 detected low 
positive signals for HIV DNA copies of pol and gag. However, there was no 
consistent trend and the highest number of detected HIV DNA copies was 
calculated to be in the double digits. 
 For the newest batch of PBMCs, CD4+ T lymphocytes were isolated to 
increase the sensitivity and accuracy of the assay; moreover, PFGE was utilized 
to remove unintegrated HIV species from the extracted DNA. By using an 
adequate amount (1000 ng) of DNA material per well and increasing the number 
of replicates per sample, Table 5 illustrates that ddPCR can achieve a limit of 






Table 5. Summary of ddPCR Results from Child. 
 
Reproducibility and Robustness of ddPCR from RAVEN Samples 
 PBMCs from two HIV-positive donors and one HIV-negative donor were 
tested for copies of gag by ddPCR. Figure 10 illustrates three complete technical 
replicates that were run with the same samples under identical conditions. 
Figure 8 illustrates no statistically significant difference between runs (P = 0.25). 
The standard deviations of the Negative Control, RAVEN 3, CARE 215 were 0, 
31.04, and 198.3 respectively. 
 To test the robustness of ddPCR and its ability to measure changes in the 
reservoir, a limiting dilution was done with the RAVEN 3 sample in 12 
replicates. 500000 CD4+ T lymphocytes were plated in the first row and 1:3 
dilutions were performed until the last row. Figure 11 illustrates that changes in 













PFGE and Integrated HIV DNA 
 By using the automated BluePippen PFGE platform, we removed a large 
fraction of lower molecular weight DNA species from our samples. The 15 kb 
cutoff causes episomal HIV DNA such as 1- and 2-LTR circles to be almost 
completely eliminated from subsequent ddPCR analysis, and should therefore 
lead to a more accurate measurement of integrated DNA in the latent HIV 
reservoir. TapeStation 2200 electropherograms also show a similar purification 
effectiveness between DNA extracted from cell lines and DNA extracted from 
patient samples. 
 Compared to the Alu-gag qPCR assay, findings from previous laboratory 
colleagues have shown that results correlate well and are comparable (Lada et 
al., 2018). Unlike traditional direct current (DC) agarose gel electrophoresis, the 
BluePippen PFGE platform utilizes alternating current (AC) that allow for 
changes in current direction based on specific time intervals. Theoretically, this 
allows for an improved separation between the different molecular weight DNA 
species. In addition, the pre-made gel cassettes separate each lane with a plastic 
blockade and prevents contamination between precious samples. Finally, this 
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automated platform allows for the user to complete other experiments during the 
PFGE run. The program will automatically stop once elution is complete and 
samples can remain in the well safely for hours with minimal evaporation  
 
Improving Upon the 0.75% Agarose High Pass Gel Cassette 
 In the original designed protocol, the 0.75% Agarose High Pass Gel 
Cassette was used. Normally, ddPCR assays recommend a load of 1000 ng per 
well to maximize sensitivity to increase the limit of detection. However, only 5 
ug of genomic DNA maximum could be loaded into each lane per the 
manufacturer’s recommendations. This means that an input of 5 ug of DNA 
would typically lead to an output of 2 ug of high molecular weight DNA, 
sufficient only for two ddPCR replicates. Furthermore, the median recovery rate 
of around 40% further complicates this issue. Keeping in mind that one lane per 
gel cassette is required for the molecular weight marker and that each run 
required about 6 hours to complete, this process would clearly be time-
consuming and expensive for a large cohort of samples or if a high amount of 
DNA is required.  
 With the RAVEN project totaling around 120 PBMC specimens, we 
decided to test the new High Pass Plus Gel Cassette from BluePippen to optimize 
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our workflow. Though the gel cassette can still process a maximum of four 
samples per run, the initial load could now be doubled to 10 ug of DNA. Even if 
the recovery remained at 40%, we would have enough DNA post-PFGE to run 
our ddPCR samples in triplicates. However, experiments with both U1 DNA and 
genomic DNA have shown that the High Pass Plus Gel Cassette has an DNA 
recovery of closer to 70%, allowing us to have more DNA to work with after the 
removal of episomal DNA species such as 1- and 2-LTR circles. 
 The run time on the High Pass Plus Gel Cassette has also been reduced 
compared to its counterpart. Most runs were complete near the three-and-a-half-
hour mark, with some pushing the four-hour mark. For laboratories with just one 
BluePippen machine, up to eight samples could still be easily processed within a 
day. Although it has been suggested that a second run can be completed 
overnight on the 0.75% Agarose High Pass Gel Cassette, the manufacturer 
specifically noted that gel cassettes should not be left in the machine overnight. 
This is because the evaporation of the electrophoresis buffer could cause damage 
to the LED electrodes responsible for size separation and that the quality of the 
eluted DNA product could be compromised if not suspended in a proper 




Quality of Integrated DNA from the High Pass Plus Gel Cassette 
 Initially, we had worries that a high DNA load with a shorter run time 
would result in insufficient removal of low molecular weight DNA species. 
However, comparing both U1 DNA samples as well as genomic DNA samples 
from chronically-infected HIV patients, the High Pass Plus Gel Cassette was an 
equally effective option for DNA size selection. 
 It is important to note that one downside of the High Pass Plus Gel 
Cassette is that the cutoff value can only be set above 15 kb. Laboratories with a 
specific need to keep DNA species <15 kb should use the 0.75% Agarose High 
Pass Gel Cassette, since it is much more flexible in its start and stop separation 
points. Users of the BluePippen platform should also remember to update their 
machine’s firmware as the pre-programmed protocol for the High Pass Plus Gel 
Cassette is available only in the latest version. 
 
Using ddPCR to Maximize Sensitivity and Reproducibility 
 As mentioned before, qPCR has been the most common PCR assay for 
measuring the latent HIV reservoir. However, its quantitation methods are 
indirect. Depending on experimental design and conditions, only 20% to 70% of 
the total integration events can be detected in a given alu-gag qPCR run. To 
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correct for this, a correction factor generated from a standard integration cell line 
is multiplied onto the original results (Liszewski et al., 2009).  
 PFGE with ddPCR offers a potential solution for this issue. It allows for a 
direct measurement of DNA copies within each well without the need for post-
analysis statistical correction. Data published from multiple studies have also 
noted the increased sensitivity, reproducibility, precision, accuracy, and scability 
compared to qPCR assays (Strain et al., 2013; Zhao et al., 2016) .  
In our collaboration with UTHealth to measure the latent HIV reservoir 
for the infant born to an infected mother, it was crucial that we used ddPCR for 
our measurements. We needed to maximize sensitivity as the HIV copy 
frequencies for gag and pol were at most in the single digits. The results did 
initially seem to suggest that the latent HIV reservoir of the infant had risen since 
2016; but having tested the most recent PBMC and CD4+ T lymphocyte samples 
in nine replicates, we are more confident that the previous data may have been a 
result of contamination or technical erros. 
 For a larger cohort of samples like the RAVEN project, we were interested 
to confirm that ddPCR could offer unparalleled reproducibility Not only did our 
results show an extremely low variance between each sample per run, even the 
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variance between replicate wells has been shown to be relatively small with 
properly-set thresholds and the removal of false positives. 
Figure 12 illustrates a composite 2D scatter plot of 24 ddPCR wells with a 
manually set threshold. The X-axis illustrates positive events for HIV gag copies 
(HEX dye) and the Y-axis illustrates positive events for HIV tat/rev copies (FAM 
dye). False double-positive events like the single one below can be removed prior 










Limitations and Future Applications of PFGE 
 The implementation of the High Pass Plus Gel Cassette has definitely 
helped us to optimize our workflow. However, although we can purify high 
molecular weight DNA species with an improved recovery in less time, there are 
still many checkpoints that must be done to ensure that the PFGE runs smoothly. 
Perhaps the most crucial is the prevention of air bubbles in the pre-made gel 
cassette that can completely ruin separation and elution in a lane. We have yet to 
encounter this issue in our experiments, but users should carefully inspect for air 
bubbles behind the elution wells and remove them before proceeding. Other 
important checkpoints include thoroughly cleaning the PFGE platform with a 
rinse cassette and calibrating the LED electrodes before each run. 
 One potentially unexplored use of the BluePippen PFGE platform by is its 
ability to collect the low molecular weight DNA flow-through in a separate 
chamber. The eluates in this chamber include 1- and 2-LTR circles as well as high 
molecular weight DNA that has been sheared by the PFGE process. If one desires 
to analyze and measure unintegrated DNA in addition to integrated DNA, these 
gel cassettes could certainly prove useful. The low molecular weight DNA 
species are highly diluted in electrophoresis buffer but can be concentrated by 
ethanol precipitation or with a vacuum concentrator. Downstream ddPCR 
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analysis can also be carried out for the low molecular weight DNA species to 
verify the purification of 1- and 2-LTR circles in the flow-through. 
 
Limitations and Future Applications of ddPCR 
 ddPCR results generated in this project comes exclusively from the Bio-
Rad ddPCR platform. Despite the the high cost of instruments and reagents, the 
QX200 does still detect false positive events during almost every reading that 
skews the accuracy of the data. Even in non-template negative control wells, false 
positive signals can be seen frequently. Moreover, the default thresholds 
generated by the Bio-Rad QuantaSoft Software also lead to incorrect calls in 
categorizing an event as positive or negative. However, the majority of these 
errors can be addressed by manually re-analyzing the raw fluorescence data. 
Still, we are not certain if these errors are specific to the Bio-Rad ddPCR platform 
or due to some shared aspects of the ddPCR process. 
 That said, ddPCR is still a robust method of measuring integrated HIV 
DNA compared to the Alu-gag qPCR. The RAVEN project, upon completion, 
will allow for the statistically comparison of data between multiple laboratories 
to confirm the intra-lab precision and inter-lab reproducibility of ddPCR for the 
quantification of the latent HIV reservoir. With the multitude of HIV cure 
 
 45 
strategies still being developed and tested, I firmly believe that ddPCR paired 
with PFGE will become be an attractive option to detect changes within the latent 
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